• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Biogen Idec

edit

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion.

Recent Milestones

edit

• 
  Biogen Idec invested in Museum of Science. (9/12/12)
  Posted 9/12/12 at 7:22pm via masshightech.com
• 
  Biogen Idec — Biogen Idec Fully Acquires Biogen Dompé Joint Ventures (9/6/11)
  Posted 9/6/11 at 7:32pm via yahoo.com
• 
  Biogen Idec — has bought a subsidiary of Swiss firm Neurimmune Holding AG in a move that will give Biogen potential treatments for neurodegenerative disease like Parkinson’s disease, at a total potential cost of $427 million (12/21/10)
  Posted 12/21/10 at 7:08am via masshightech.com
• 
  Biogen Idec — has awarded 12 fellowships to universities and medical centers researching multiple sclerosis, as part of a program the company started in 2006 to further education in the therapeutic area that forms the core of Biogen’s business. (12/7/10)
  Posted 12/8/10 at 8:47am via masshightech.com
• 
  Biogen Idec — announced it will cut its work force by 13 percent, closing a site in San Diego and consolidating sites in Eastern Massachusetts into the large sites in Weston and Cambridge (11/3/10)
  Posted 11/4/10 at 6:22am via masshightech.com
• 
  Biogen Idec — Biogen Idec Inc. is reporting that revenues were $1.2 billion in the third quarter of 2010, up 5 percent from revenue of $801.7 million for the corresponding period last year (10/26/10)
  Posted 10/27/10 at 3:14am via masshightech.com
• 
  Biogen Idec invested in iPierian. (9/9/10)
  Posted 7/8/10 at 7:02pm via dowjones.com
• 
  Biogen Idec — Biogen CEO calls it quits after 7 turbulent years (1/5/10)
  Posted 1/6/10 at 3:38am via fiercebiotech.com
• 
  Biogen Idec invested in Virdante Pharmaceuticals. (11/25/09)
  Posted 10/29/09 at 6:27pm via onbiovc.com
• 
  Biogen Idec invested in Intellikine. (7/22/09)
  Posted 7/28/09 at 1:25pm via onbiovc.com
• 
  Biogen Idec invested in CalciMedica. (1/4/09)
  Posted 6/15/09 at 7:24pm via onbiovc.com
• 
  Biogen Idec invested in Provasculon. (3/24/08)
  Posted 12/18/09 at 3:24am via partners.org
• 
  Biogen Idec invested in Raven Biotechnologies. (10/12/05)
  Posted 7/1/10 at 3:44am via freshnews.com

Investments

Videos

Sources

Biogen CEO calls it quits after 7 turbulent years (fiercebiotech.com) [edit]
Biogen revenue boosted by MS drugs (masshightech.com) [edit]
Biogen to cut work force by 13 percent (masshightech.com) [edit]
Biogen grows MS fellowship program (masshightech.com) [edit]
Biogen buys Neurimmune unit for up to $427M (masshightech.com) [edit]
Biogen Idec Fully Acquires Biogen Dompé Joint Ventures (finance.yahoo.com) [edit]
1. Museum of Science gets $1M from bio foundation (masshightech.com) [edit]
2. IPierian Announces Second Close Of Series B Financing At $28M (fis.dowjones.com) [edit]
3. Virdante Pharmaceuticals, Inc.: Series A $30M (onbiovc.com) [edit]
4. Intellikine, Inc.: Series B $51M (onbiovc.com) [edit]
5. CalciMedica, Inc.: Series C $4M (onbiovc.com) [edit]
6. Provasculon launches with $6M and new home at Biogen incubator (partners.org) [edit]
7. RAVEN BIOTECHNOLOGIES INC. RAISES $48.3 MILLION IN SERIES D FINANCING (freshnews.com) [edit]